| Entry |
|
|---|
| Name |
Cytarabine hydrochloride (USAN) |
|---|
| Formula |
C9H13N3O5. HCl
|
|---|
| Exact mass |
279.0622
|
|---|
| Mol weight |
279.6776
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
|
|---|
| Remark |
| Product (DG00686): | D00168<JP/US> D03046<JP> |
|
|---|
| Efficacy |
Antineoplastic, Antimetabolite |
|---|
| Comment |
Arabinofuranosyl derivative
|
|---|
| Target |
DNA polymerase |
|---|
| Interaction |
|
|---|
| Structure map |
| map07041 | Antineoplastics - antimetabolic agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01B ANTIMETABOLITES
L01BC Pyrimidine analogues
L01BC01 Cytarabine
D03637 Cytarabine hydrochloride (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG00686 Cytarabine
D03637 Cytarabine hydrochloride
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG00686 Cytarabine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 18
1 C1y C 23.1685 -16.8344
2 N4y N 24.5093 -16.4132
3 O2x O 22.0336 -16.0095
4 C1y C 22.7357 -18.1626
5 C8y C 25.7140 -17.1098
6 C8x C 24.4994 -15.0145
7 C1y C 20.8985 -16.8344
8 C1y C 21.3315 -18.1626
9 O1a O 23.5547 -19.2977
10 N5x N 26.9259 -16.4039
11 O5x O 25.7182 -18.5096
12 C8x C 25.7113 -14.3086
13 C1b C 19.5646 -16.4016
14 O1a O 20.5124 -19.2977
15 C8y C 26.9216 -15.0039
16 O1a O 18.5290 -17.3434
17 N1a N 28.1349 -14.3039
18 X Cl 29.2599 -18.8299
BOND 18
1 1 2 1 #Up
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 1
7 4 8 1
8 4 9 1 #Up
9 5 10 1
10 5 11 2
11 6 12 2
12 7 13 1 #Up
13 8 14 1 #Down
14 10 15 2
15 13 16 1
16 15 17 1
17 7 8 1
18 12 15 1
|
|---|
